Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.55 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981531 | 0.87 | SLC6A9 (0.57) | OPRK1OPRM1OPRL1OPRD1HSD17B10 | |
| SCHEMBL21688404 | 0.86 | OPRK1 (0.57) | OPRK1OPRM1OPRL1OPRD1HSD17B10 | |
| SCHEMBL21634299 | 0.86 | HSD17B10 (0.62) | OPRK1OPRM1OPRL1OPRD1HSD17B10 | |
| SCHEMBL318707 | 0.85 | HSD17B10 (0.65) | OPRK1OPRM1OPRL1OPRD1HSD17B10 | |
| SCHEMBL1761014 | 0.83 | OPRL1 (0.64) | OPRK1OPRM1OPRL1OPRD1HSD17B10 | |
| SCHEMBL5799198 | 0.82 | OPRK1 (0.55) | OPRK1OPRM1OPRL1OPRD1HSD17B10 | |
| SCHEMBL14263125 | 0.82 | CCR3 (0.57) | OPRK1OPRM1OPRL1OPRD1SLC18A3 | |
| SCHEMBL21634315 | 0.82 | HSD17B10 (0.60) | OPRK1OPRM1OPRL1OPRD1HSD17B10 | |
| SCHEMBL14543210 | 0.82 | HSD17B10 (0.60) | OPRK1OPRM1OPRL1OPRD1HSD17B10 | |
| SCHEMBL21634302 | 0.82 | SLC18A3 (0.61) | OPRK1OPRM1OPRL1OPRD1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354418-B2 | Thiazolyl-dihydro-quinazolines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20090131424-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| US-7517995-B2 | Thiazolyl-dihydro-cyclopentapyrazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070259855-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
| US-20070238746-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259855-A1 | THIAZOLYL-DIHYDRO-INDAZOLE | ROR1, RORB, RORA | OPRK1 1491/4885OPRM1 2160/4885OPRL1 3263/4885 |
| US-20070238746-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | CYP3A7, UGT2B7, UGT1A7 | OPRK1 872/4885OPRM1 1050/4885OPRL1 2366/4885 |
| US-20090131424-A1 | THIAZOLYL-DIHYDRO-CHINAZOLINE | CYP3A7, UGT2B7, UGT1A7 | OPRK1 872/4885OPRM1 1050/4885OPRL1 2366/4885 |
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | REN, ROR1, RORB | OPRK1 1052/4885OPRM1 1527/4885OPRL1 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.